 |
 |
 |
 |
 |
 |
 |
 |
Potentia is an early stage biotechnology company focused on developing innovative therapeutics, primarily in the area of age-related macular degeneration and other inflammatory ocular diseases. Potentia assembles its pipeline of anti-inflammatory products through a combination of in-licensing of preclinical compounds and in-house research and development.
Potentia announces the in-licensing of a pre-clinical compound, POT-4, a member of the Compstatin family of complement inhibitors.
more info »
- July 2006 Potentia Pharmaceuticals licences complement inhibitor Compstatin from the University of Pennsylvania
more » - June 2006 Potentia Pharmaceuticals awarded two Phase I STTR grants from the National Eye Institute
more » - April 2006 Potentia Pharmaceuticals hosts reception at the 2006 ARVO annual meeting in Fort Lauderdale.
more »
